A detailed history of Tri Locum Partners LP transactions in Argenx Se stock. As of the latest transaction made, Tri Locum Partners LP holds 62,474 shares of ARGX stock, worth $35.2 Million. This represents 9.05% of its overall portfolio holdings.

Number of Shares
62,474
Previous 74,558 16.21%
Holding current value
$35.2 Million
Previous $32.1 Million 5.68%
% of portfolio
9.05%
Previous 8.28%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $5.25 Million - $6.67 Million
-12,084 Reduced 16.21%
62,474 $33.9 Million
Q2 2024

Aug 14, 2024

BUY
$356.01 - $451.55 $16.6 Million - $21 Million
46,577 Added 166.46%
74,558 $32.1 Million
Q1 2024

May 15, 2024

BUY
$356.95 - $413.29 $1.36 Million - $1.57 Million
3,799 Added 15.71%
27,981 $11 Million
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $3.33 Million - $4.98 Million
9,836 Added 68.56%
24,182 $9.2 Million
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $5.3 Million - $7.87 Million
14,346 New
14,346 $7.05 Million
Q4 2022

Feb 14, 2023

SELL
$342.17 - $402.31 $21.5 Million - $25.3 Million
-62,853 Reduced 97.98%
1,299 $492,000
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $6.38 Million - $7.35 Million
-18,583 Reduced 22.46%
64,152 $22.6 Million
Q2 2022

Aug 15, 2022

BUY
$269.58 - $378.88 $12.6 Million - $17.8 Million
46,855 Added 130.59%
82,735 $31.3 Million
Q1 2022

May 16, 2022

SELL
$254.45 - $351.06 $3.17 Million - $4.38 Million
-12,467 Reduced 25.79%
35,880 $11.3 Million
Q4 2021

Feb 14, 2022

BUY
$272.01 - $353.03 $13.2 Million - $17.1 Million
48,347 New
48,347 $16.9 Million
Q3 2021

Nov 15, 2021

SELL
$295.0 - $350.58 $1.89 Million - $2.25 Million
-6,408 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$257.11 - $319.92 $1.65 Million - $2.05 Million
6,408 New
6,408 $1.93 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Tri Locum Partners LP Portfolio

Follow Tri Locum Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Tri Locum Partners LP with notifications on news.